19
views
0
recommends
+1 Recommend
3 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The COVID-19 pandemic has currently overtaken every other health issue throughout the world. There are numerous ways in which this will impact existing public health issues. Here we reflect on the interactions between COVID-19 and tuberculosis (TB), which still ranks as the leading cause of death from a single infectious disease globally. There may be grave consequences for existing and undiagnosed TB patients globally, particularly in low and middle income countries (LMICs) where TB is endemic and health services poorly equipped. TB control programmes will be strained due to diversion of resources, and an inevitable loss of health system focus, such that some activities cannot or will not be prioritised. This is likely to lead to a reduction in quality of TB care and worse outcomes. Further, TB patients often have underlying co-morbidities and lung damage that may make them prone to more severe COVID-19. The symptoms of TB and COVID-19 can be similar, with for example cough and fever. Not only can this create diagnostic confusion, but it could worsen the stigmatization of TB patients especially in LMICs, given the fear of COVID-19. Children with TB are a vulnerable group especially likely to suffer as part of the “collateral damage”. There will be a confounding of symptoms and epidemiological data through co-infection, as happens already with TB–HIV, and this will require unpicking. Lessons for COVID-19 could be learned from the vast experience of running global TB control programmes, while the astonishingly rapid and relatively well co-ordinated response to COVID-19 demonstrates how existing programmes could be significantly improved.

          Related collections

          Most cited references7

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          The South African Tuberculosis Care Cascade: Estimated Losses and Methodological Challenges

          Abstract Background While tuberculosis incidence and mortality are declining in South Africa, meeting the goals of the End TB Strategy requires an invigorated programmatic response informed by accurate data. Enumerating the losses at each step in the care cascade enables appropriate targeting of interventions and resources. Methods We estimated the tuberculosis burden; the number and proportion of individuals with tuberculosis who accessed tests, had tuberculosis diagnosed, initiated treatment, and successfully completed treatment for all tuberculosis cases, for those with drug-susceptible tuberculosis (including human immunodeficiency virus (HIV)–coinfected cases) and rifampicin-resistant tuberculosis. Estimates were derived from national electronic tuberculosis register data, laboratory data, and published studies. Results The overall tuberculosis burden was estimated to be 532005 cases (range, 333760–764480 cases), with successful completion of treatment in 53% of cases. Losses occurred at multiple steps: 5% at test access, 13% at diagnosis, 12% at treatment initiation, and 17% at successful treatment completion. Overall losses were similar among all drug-susceptible cases and those with HIV coinfection (54% and 52%, respectively, successfully completed treatment). Losses were substantially higher among rifampicin- resistant cases, with only 22% successfully completing treatment. Conclusion Although the vast majority of individuals with tuberculosis engaged the public health system, just over half were successfully treated. Urgent efforts are required to improve implementation of existing policies and protocols to close gaps in tuberculosis diagnosis, treatment initiation, and successful treatment completion.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            COVID-19 pandemic in west Africa

            The coronavirus disease 2019 (COVID-19) outbreak, which started in the Hubei province of China in 2019, has now spread to all continents, affecting 177 countries by March 27, 2020. 1 Successful efforts in containing the COVID-19 virus in Asia resulted in WHO declaring Europe as the epicentre of the disease on March 13. 2 Whether warmer temperatures will slow the spread of the COVID-19 virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been a point of much speculation. This hypothesis has led some European countries to produce initial policies relying on decreased transmission rates during the summer months, 3 and the belief that African countries will face smaller epidemics than their European counterparts. However, no strong evidence base exists for such claims; SARS-CoV-2 might have simply arrived later to warmer countries. We used data from the COVID-19 data repository of the Johns Hopkins Center for Systems Science and Engineering (Baltimore, MD, USA) to plot the cumulative number of cases since the diagnosis of both the first patient and the first five patients by country, both in Europe and Africa (figure ). Although the first confirmed COVID-19 cases occurred later in west Africa than in Europe, once these first cases were confirmed in west Africa, the expansion in the number of confirmed COVID-19 was rapid. Of particular concern are Burkina Faso and Senegal, which saw sharp increases in the number of cases soon after the initial cases were confirmed in these countries. Cases in both countries might evolve in a similar way to what was observed in European countries with the most expansive epidemics (ie, Italy and Spain, where SARS-CoV-2 spread quickly after case number five was detected). Senegal also confirmed its first three cases of community transmission on March 21, 4 suggesting more cases in this country than the 119 confirmed on March 27. Figure Evolution of COVID-19 pandemic Curves show how the pandemic initially evolved in west African countries (continuous lines) compared with European countries (dashed lines) and other African countries (dotted lines): from the first case diagnosed in the country (A); and from the fifth case diagnosed in the country (B). Graphs were generated with data downloaded from the COVID-19 data repository of the Johns Hopkins Center for Systems Science and Engineering on March 23, 2020. COVID-19=coronavirus disease 2019. The impact of a similar epidemic as currently seen in Europe would be devastating in west Africa. Although some west African countries have measures in place from the 2014 Ebola epidemic, the region includes some of the poorest countries in the world (according to World Bank data, nine of the 25 poorest countries are in the region). In addition, many west African countries have poorly resourced health systems, rendering them unable to quickly scale up an epidemic response. Most countries in the region have fewer than five hospital beds per 10 000 of the population and fewer than two medical doctors per 10 000 of the population (based on WHO global health observatory data), and half of all west African countries have per capita health expenditures lower than US$50 (based on WHO global health expenditure data. In contrast, Italy and Spain have 34 and 35 hospital beds, respectively, per 10 000 of the population, 41 medical doctors per 10 000 of the population, and US$2840 and US$2506 per capita expenditure. Despite having young populations (old age is a major risk factor for severe forms of COVID-19 and mortality), some west African countries have rates of other risk factors similar to European countries. For instance, 27% of Gambians have hypertension 5 and 6% have diabetes. 6 We believe the epidemic has started later in west Africa than for other regions globally because of the limited international air traffic, rather than the climate conditions. Now that community transmission is ongoing in some countries, the amount of time to prepare an epidemic response is limited. Early identification of confirmed cases, swift contact tracing with physical isolation, community engagement, and health systems measures are all necessary to avert the potentially harmful consequences of an epidemic in the region. To conclude, early comparisons between the number of confirmed cases in the worst affected European countries and the west African countries with confirmed COVID-19 cases do not support the hypothesis that the virus will spread more slowly in countries with warmer climates. In the case of west Africa, a rapid acceleration in the number of cases could quickly overwhelm already vulnerable health systems. Swift action to control further spread of the virus, and to improve the response capabilities of affected countries in west Africa is therefore urgent.
              Bookmark
              • Record: found
              • Abstract: found
              • Book: not found

              Global tuberculosis report 2019

              WHO has published a global TB report every year since 1997. The main aim of the report is to provide a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of recommended global TB strategies and targets endorsed by WHO's Member States, broader development goals set by the United Nations (UN) and targets set in the political declaration at the first UN high-level meeting on TB (held in September 2018).<br> <br> The 2019 edition of the global TB report was released on 17 October 2019. The data in this report are updated annually. Please note that direct comparisons between estimates of TB disease burden in the latest report and previous reports are not appropriate. The most recent time-series of estimates are published in the 2019 global TB report.
                Bookmark

                Author and article information

                Contributors
                marclipman@nhs.net
                Journal
                Ann Clin Microbiol Antimicrob
                Ann. Clin. Microbiol. Antimicrob
                Annals of Clinical Microbiology and Antimicrobials
                BioMed Central (London )
                1476-0711
                23 May 2020
                23 May 2020
                2020
                : 19
                : 21
                Affiliations
                [1 ]GRID grid.415063.5, ISNI 0000 0004 0606 294X, Vaccines and Immunity Theme, , Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine (MRCG at LSHTM), ; Atlantic Boulevard, Fajara, The Gambia
                [2 ]GRID grid.8991.9, ISNI 0000 0004 0425 469X, Faculty of Infectious and Tropical Diseases, , London School of Hygiene and Tropical Medicine (LSHTM), ; Keppel Street, London, UK
                [3 ]GRID grid.83440.3b, ISNI 0000000121901201, UCL Centre for Clinical Microbiology, Royal Free Campus, , University College London, ; London, UK
                [4 ]GRID grid.83440.3b, ISNI 0000000121901201, UCL-TB & UCL Respiratory, Division of Medicine, , University College London, ; London, UK
                [5 ]GRID grid.437485.9, ISNI 0000 0001 0439 3380, Respiratory Medicine, , Royal Free London NHS Foundation Trust, ; London, UK
                Article
                363
                10.1186/s12941-020-00363-1
                7245173
                32446305
                4c03ff14-8fb6-485d-835b-422994f725d5
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 10 April 2020
                : 19 May 2020
                Categories
                Review
                Custom metadata
                © The Author(s) 2020

                Infectious disease & Microbiology
                tuberculosis,covid-19,pandemic,poverty,africa,children,isolation,transmission,global,co-morbidity

                Comments

                Comment on this article